Table 1. Clinical characteristics of the study population.
| Overall population (N = 1,769) | Subgroup TNF-α/IL-6 (N = 502) | |||||||||||||||||
| Median | Minimum | Maximum | Median | Minimum | Maximum | |||||||||||||
| Age (y) | 38 | 14 | 91 | 37 | 15 | 69 | ||||||||||||
| BMI (kg/m2) | 27.6 | 16.3 | 86.5 | 26.9 | 17.4 | 55.3 | ||||||||||||
| Habitual physical activity score* | 8.13 | 2.27 | 11.88 | 8.13 | 3.51 | 10.75 | ||||||||||||
| Fasting glucose (mmol/L) | 5.10 | 3.00 | 7.00 | 5.06 | 3.00 | 6.94 | ||||||||||||
| Glucose 120 min OGTT (mmol/L) | 6.17 | 2.44 | 11.06 | 6.06 | 2.78 | 11.06 | ||||||||||||
| HOMA-IR (mmol*mU/L2) | 1.90 | 0.27 | 25.52 | 1.59 | 0.32 | 25.52 | ||||||||||||
| ISI OGTT (*1015 L2/mol2) | 12.8 | 1.1 | 69.7 | 14.7 | 1.4 | 65.1 | ||||||||||||
| AUCIns 0–30/AUCGlc 0–30 (*10−9) | 34.6 | 6.0 | 289.1 | 31.9 | 7.5 | 264.9 | ||||||||||||
| AUCC-Pep 0–120/AUCGlc 0–120 (*10−9) | 310 | 91 | 841 | 306 | 109 | 816 | ||||||||||||
| TNF-α (ng/L) | – | – | – | 1.34 | 0.06 | 136.00 | ||||||||||||
| IL-6 (ng/L) | – | – | – | 0.64 | 0.02 | 25.93 | ||||||||||||
| Leukocyte number (µl−1)** | 6,270 | 337 | 18,030 | 6,120 | 337 | 16,200 | ||||||||||||
| C-reactive protein (mg/dL)** | 0.18 | 0.01 | 4.79 | 0.10 | 0.01 | 4.39 | ||||||||||||
| Total cholesterol (mg/dL)** | 189 | 63 | 468 | 187 | 67 | 350 | ||||||||||||
| LDL-cholesterol (mg/dL)** | 116 | 15 | 279 | 115 | 17 | 223 | ||||||||||||
| HDL-cholesterol (mg/dL)** | 52 | 24 | 138 | 52 | 27 | 110 | ||||||||||||
| Overall population (N = 1,769) | Subgroup TNF-α/IL-6 (N = 502) | |||||||||||||||||
| Gender | Glucose tolerance status | Gender | Glucose tolerance status | |||||||||||||||
| women | men | NGT | IFG | IGT | IFG+IGT | women | men | NGT | IFG | IGT | IFG+IGT | |||||||
| Number | 1,159 | 610 | 1,248 | 199 | 174 | 148 | 301 | 201 | 373 | 44 | 48 | 37 | ||||||
| Proportion (%) | 65.5 | 34.5 | 70.6 | 11.2 | 9.8 | 8.4 | 60.0 | 40.0 | 74.3 | 8.8 | 9.5 | 7.4 | ||||||
AUC – area under the curve; BMI – body mass index; C-Pep – C-peptide; Glc – glucose; HDL – high-density lipoprotein; HOMA-IR – homeostasis model assessment of insulin resistance; IFG – impaired fasting glycaemia; IGT – impaired glucose tolerance; IL – interleukin; Ins – insulin; ISI – insulin sensitivity index; LDL – low-density lipoprotein; NGT – normal glucose tolerance; OGTT – oral glucose tolerance test; TNF – tumour necrosis factor; *available from 1,331 subjects of the overall population and from 446 subjects of the TNF-α/IL-6 subgroup; **available from 1,687 subjects of the overall population and from 493 subjects of the TNF-α/IL-6 subgroup.